| 000 | 01619 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513090259.0 | ||
| 264 | 0 | _c19960610 | |
| 008 | 199606s 0 0 eng d | ||
| 022 | _a0007-1048 | ||
| 024 | 7 |
_a10.1046/j.1365-2141.1996.352889.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWisløff, F | |
| 245 | 0 | 0 |
_aMeasurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. _h[electronic resource] |
| 260 |
_bBritish journal of haematology _cMar 1996 |
||
| 300 |
_a604-13 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelphalan _xadministration & dosage |
| 650 | 0 | 4 |
_aMultiple Myeloma _xcomplications |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 | _aSurveys and Questionnaires |
| 700 | 1 | _aEika, S | |
| 700 | 1 | _aHippe, E | |
| 700 | 1 | _aHjorth, M | |
| 700 | 1 | _aHolmberg, E | |
| 700 | 1 | _aKaasa, S | |
| 700 | 1 | _aPalva, I | |
| 700 | 1 | _aWestin, J | |
| 773 | 0 |
_tBritish journal of haematology _gvol. 92 _gno. 3 _gp. 604-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1365-2141.1996.352889.x _zAvailable from publisher's website |
| 999 |
_c8615069 _d8615069 |
||